Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Herishanu Y, Rahav G, Levi S, Braester A, et al. Blood 2022;139:678-685.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Herishanu Y, Rahav G, Levi S, Braester A, et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination. Blood 2022;139:678-685.
PMID: 34861036